Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...
BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapiesExpected 2026 oncology ...
While rates of cancer diagnosis under age 50 have risen in recent years, this has not translated into increased cancer ...
A man was given two years to live after a colon cancer diagnosis. Now he's healthy thanks to combination of medicine and the ...
J&J shares positive long-term results of Rybrevant study for RAS/BRAF wild-type metastatic colorectal cancer at ASCO ...
In about 5–10% of colorectal cancer patients, hereditary factors play a role, with higher percentages among younger patients.
Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR Combination achieved encouraging median DOR of almost 17 ...
Doctors are alarmed by a sharp rise in bowel cancer among people under 50, with early research pointing to modern diets, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback